Company news
Quantum Cyber N.V. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update
February 16, 2026
Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
January 13, 2026
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
November 17, 2025
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
November 11, 2025
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
October 7, 2025
Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
September 22, 2025
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
September 1, 2025
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
August 12, 2025
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
August 3, 2025
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
July 22, 2025
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
July 14, 2025
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
June 24, 2025
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
June 9, 2025
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants
May 18, 2025
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
May 15, 2025
Mainz Biomed Enters into Technology Partnership with EDX Medical Group
April 28, 2025
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
April 27, 2025
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
March 31, 2025
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
March 26, 2025
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
March 12, 2025
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
February 10, 2025
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
January 26, 2025
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
January 20, 2025
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
December 18, 2024
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
December 15, 2024
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
December 11, 2024
Mainz Biomed Announces Stock Split
November 28, 2024
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
November 11, 2024
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
October 20, 2024
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
October 7, 2024
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
September 17, 2024
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
September 3, 2024
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
July 24, 2024
Mainz BioMed Seeks FDA Breakthrough Device Designation for Advanced Colorectal Cancer Test
July 18, 2024
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
July 8, 2024
Mainz Biomed Provides Half Year 2024 Corporate Update
July 1, 2024
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
June 2, 2024
Mainz Biomed Reports Results of 2024 Annual General Meeting
May 30, 2024
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
May 27, 2024
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
May 19, 2024
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
May 6, 2024
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
April 24, 2024
Mainz Biomed Reports Full Year 2023 Financial Results
April 8, 2024
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
March 4, 2024
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
February 21, 2024
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
February 20, 2024
Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
February 5, 2024
Mainz Biomed Provides Year-End Corporate Review 2023
January 8, 2024
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
December 18, 2023
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
December 4, 2023
Decks
- Investor Presentation (September 2026)
Investor deck · 14 slides · Sep 25, 2026
- Investor Presentation (July 2026)
Investor deck · 21 slides · Jul 24, 2026
- Investor Presentation (June 2026)
Investor deck · 19 slides · Jun 3, 2026